Nordic equity fund acquires Danish cancer diagnostics company  

2007.03.01
Nordic equity fund EQT V has signed an agreement to acquire Denmark's Dako A/S, one of the world's leading cancer diagnostics companies for DKK 7.3 bn
Nordic equity fund EQT V has signed an agreement to acquire Denmark's Dako A/S, one of the world's leading cancer diagnostics companies, for DKK 7.3 bn (USD 1.3 bn).  Dako's current main shareholders include descendants of the company’s founder Niels Harboe (61%), Novo Nordisk A/S (27%) and others (12%).
 
Ole Andersen of EQT Partners says: "We are pleased to add Dako to our portfolio. The company has a powerful position in an interesting growth market for cancer diagnostics. Our intention is to support the management in further development of the company in accordance with its strategy. Dako will remain headquartered in Copenhagen, and we will continue to build the Dako brand to realize its full potential."
 
Dako develops, manufactures and markets cell-based cancer diagnostics for clinical diagnostics and research to hospitals and laboratories worldwide. The company employs 1,300 people and has a presence in 20 countries. In 2006, Dako generated sales of DKK 1.7 bn (USD 306 m), a 10% growth on the previous year. The news was reported on Dako's website.
 
Link > Dako  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×